Sun Pharma Advanced Research Company Limited has informed the Exchange about Updates on Vibozilimod (SCD-044)
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 21.1 pts less than Nifty Microcap 250 and 20.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SPARC's partner Sun Pharma Industries announced top-line results from two Phase 2 trials of Vibozilimod (SCD-044): the SOLARES PsO study for moderate-to-severe Psoriasis and the SOLARES AD study for Atopic Dermatitis. Both studies failed to meet their primary endpoints at Week 16 — neither achieved 75% improvement in PASI score (Psoriasis) nor 75% improvement in EASI score (Atopic Dermatitis). SPARC and Sun Pharma will now evaluate the appropriate next steps for the drug candidate. No specific financial impact or timeline for further development has been disclosed yet.
This is a meaningful negative for SPARC, as SCD-044 is one of its key pipeline assets and Phase 2 failure significantly reduces the probability of commercialisation and any future milestone payments or royalties from its partner. The stock is likely to face selling pressure; investors should watch for the company's next update on whether development will continue, pivot, or be discontinued.